Last reviewed · How we verify

NCT05519553: PAIR-SEP

Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis

Status unknown NA Last updated 1 September 2022
What this trial tests

NA trial testing Peer support in Multiple Sclerosis, Relapsing-remitting in 60 participants. Status unknown.

Timeline
1 November 2022
Primary endpoint
1 March 2024
1 March 2026

Quick facts

Lead sponsorNantes University Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment60
Start date1 November 2022
Primary completion1 March 2024
Estimated completion1 March 2026

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 95, any sex, with Multiple Sclerosis, Relapsing-remitting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A mixed methods randomized controlled trial pilot study to assess peer support impact on relapsing-remitting multiple sclerosis patients' therapeutic adherence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Peer support impact on therapeutic adherence in patients with multiple sclerosis: a mixed-methods pilot trial protocol.
    Guilmault L, Wiertlewski S, Malloggi L, Rousseau C, et al · · 2023 · cited 1× · PMID 38159942 · DOI 10.1136/bmjopen-2022-071336

Verify or expand the search:

Other trials of Peer support

Trials testing the same drug.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05519553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing